



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	1	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-3,450,693	06-17-1969	Suzuki <i>et al.</i>	
	A2*	US-3,670,086	06-13-1972	Pryor <i>et al.</i>	
	A3*	US-3,692,907	09-19-1972	Fleming <i>et al.</i>	
	A4*	US-3,891,660	06-24-1975	Denzel <i>et al.</i>	
	A5*	US-3,899,508	08-12-1975	Wikel	
	A6*	US-3,917,624	11-04-1975	Abu El-Haj <i>et al.</i>	
	A7*	US-4,006,237	02-01-1977	Buckle <i>et al.</i>	
	A8*	US-4,053,588	10-11-1977	Konig <i>et al.</i>	
	A9*	US-4,381,344	04-26-1983	Rideout <i>et al.</i>	
	A10*	US-4,552,874	11-12-1985	Mardin <i>et al.</i>	
	A11*	US-4,563,525	01-07-1986	Campbell, Jr.	
	A12*	US-4,593,821	06-10-1986	Brule	
	A13*	US-4,668,686	05-26-1987	Meanwell <i>et al.</i>	
	A14*	US-4,690,930	09-01-1987	Takada <i>et al.</i>	
	A15*	US-4,698,346	10-06-1987	Musser <i>et al.</i>	
	A16*	US-4,753,951	06-28-1988	Takada <i>et al.</i>	
	A17*	US-4,758,574	07-19-1988	Robertson <i>et al.</i>	
	A18*	US-4,774,339	09-27-1988	Haugland <i>et al.</i>	
	A19*	US-4,775,674	10-04-1988	Meanwell <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	AU-2002239547-B2	11-30-2006	3m Innovative Properties Co		
	B2	AU-2004220534-A1	09-23-2004	3m Innovative Properties Co		
	B3	AU-2004229478-A1	10-28-2004	3m Innovative Properties Co		
	B4	AU-2004264336-A1	02-24-2005	3m Innovative Properties Co		
	B5	AU-2004268625-A1	03-10-2005	3m Innovative Properties Co		
	B6	CA-2044087-A1	12-09-1991	Roussel Uclaf		✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	2	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A20*	US-4,800,206	01-24-1989	Alig <i>et al.</i>	
	A21*	US-4,826,830	05-02-1989	Han <i>et al.</i>	
	A22*	US-4,837,378	06-06-1989	Borgman	
	A23*	US-4,880,779	11-14-1989	Gallaher	
	A24*	US-4,904,669	02-27-1990	Knoll <i>et al.</i>	
	A25*	US-4,988,714	01-29-1991	Alig <i>et al.</i>	
	A26*	US-5,187,288	02-16-1993	Kang <i>et al.</i>	
	A27*	US-5,225,183	07-06-1993	Purewal <i>et al.</i>	
	A28*	US-5,248,782	09-28-1993	Haugland <i>et al.</i>	
	A29*	US-5,274,113	12-28-1993	Kang <i>et al.</i>	
	A30*	US-5,342,784	08-30-1994	Yamada <i>et al.</i>	
	A31*	US-5,352,680	10-04-1994	Portoghese <i>et al.</i>	
	A32*	US-5,376,501	12-27-1994	Marien <i>et al.</i>	
	A33*	US-5,378,848	01-03-1995	Takada <i>et al.</i>	
	A34*	US-5,444,065	08-22-1995	Nikolaides <i>et al.</i>	
	A35*	US-5,446,160	08-29-1995	Stucky <i>et al.</i>	
	A36*	US-5,494,916	02-27-1996	Lindstrom <i>et al.</i>	
	A37*	US-5,500,228	03-19-1996	Lawter <i>et al.</i>	
	A38*	US-5,525,612	06-11-1996	Gerster	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
	B7	CA-2158996-A1	10-13-1994	Bayer Ag		
	B8	CN-1354663-A	06-19-2002	3m Innovative Properties Co		
	B9	EP-0 145 340-A2	06-19-1985	Riker Laboratories Inc		
	B10	EP-0 223 420-A1	05-27-1987	Shionogi & Co		
	B11	EP-0 310 950-A1	04-12-1989	Riker Laboratories Inc		
	B12	EP-0 385 630-A2	09-05-1990	Riker Laboratories Inc		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,959-Conf. #9672	
			Filing Date	May 22, 2006	
			First Named Inventor	Larry R. Krepski	
			Art Unit	1625	
			Examiner Name	R. J. Desai	
Sheet	3	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A39*	US-5,530,114	06-25-1996	Bennett <i>et al.</i>	
	A40*	US-5,569,450	10-29-1996	Duan <i>et al.</i>	
	A41*	US-5,571,819	11-05-1996	Sabb <i>et al.</i>	
	A42*	US-5,578,727	11-26-1996	Andre <i>et al.</i>	
	A43*	US-5,585,612	12-17-1996	Harp, Jr.	
	A44*	US-5,602,256	02-11-1997	Andre <i>et al.</i>	
	A45*	US-5,605,899	02-25-1997	Gerster <i>et al.</i>	
	A46*	US-5,612,377	03-18-1997	Crooks <i>et al.</i>	
	A47*	US-5,627,281	05-06-1997	Nikolaides <i>et al.</i>	
	A48*	US-5,644,063	07-01-1997	Lindstrom <i>et al.</i>	
	A49*	US-5,648,516	07-15-1997	Nikolaides <i>et al.</i>	
	A50*	US-5,714,608	02-03-1998	Gerster	
	A51*	US-5,731,193	03-24-1998	Mori <i>et al.</i>	
	A52*	US-5,736,553	04-07-1998	Wick <i>et al.</i>	
	A53*	US-5,741,909	04-21-1998	Gerster <i>et al.</i>	
	A54*	US-5,750,134	05-12-1998	Scholz <i>et al.</i>	
	A55*	US-5,776,432	07-07-1998	Schultz <i>et al.</i>	
	A56*	US-5,780,045	07-14-1998	McQuinn <i>et al.</i>	
	A57*	US-5,837,809	11-17-1998	Grandy <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
	B13	EP-0 389 302-A1	09-26-1990	Riker Laboratories Inc		
	B14	EP-0 425 306-A2	05-02-1991	Riker Laboratories Inc		
	B15	EP-0 510 260-A2	10-28-1992	Toyo Jozo Kk		
	B16	EP-0 645 389-A1	03-29-1995	Lonza Ag		v
	B17	EP-0 778 277-A1	06-11-1997	Pfizer		
	B18	EP-0 894 797-A1	02-03-1999	Terumo Corp		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	4	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A58*	US-5,840,744	11-24-1998	Borgman	
	A59*	US-5,854,257	12-29-1998	Armitage <i>et al.</i>	
	A60*	US-5,861,268	01-19-1999	Tang <i>et al.</i>	
	A61*	US-5,886,006	03-23-1999	Nikolaides <i>et al.</i>	
	A62*	US-5,939,047	08-17-1999	Jernberg	
	A63*	US-5,962,479	10-05-1999	Chen	
	A64*	US-5,962,636	10-05-1999	Bachmaier <i>et al.</i>	
	A65*	US-5,977,366	11-02-1999	Gerster <i>et al.</i>	
	A66*	US-6,028,076	02-22-2000	Hirota <i>et al.</i>	
	A67*	US-6,057,371	05-02-2000	Glennon	
	A68*	US-6,069,140	05-30-2000	Sessler <i>et al.</i>	
	A69*	US-6,071,949	06-06-2000	Mulshine <i>et al.</i>	
	A70*	US-6,077,349	06-20-2000	Kikuchi	
	A71*	US-6,113,918	09-05-2000	Johnson <i>et al.</i>	
	A72*	US-6,121,323	09-19-2000	Merrill	
	A73*	US-6,123,957	09-26-2000	Jernberg	
	A74*	US-6,126,938	10-03-2000	Guy <i>et al.</i>	
	A75*	US-6,194,388	02-27-2001	Krieg <i>et al.</i>	
	A76*	US-6,200,592	03-13-2001	Tomai <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B19	EP-1 082 960-A2	03-14-2001	Pfizer Prod Inc		
	B20	EP-1 097 709-A2	05-09-2001	Pfizer Prod Inc		
	B21	EP-1 145 340-A2	10-17-2001	Siemens Westinghouse Power <i>et al.</i>		
	B22	EP-1 256 582-A1	11-13-2002	Hokuriku Pharmaceutical		
	B23	EP-1 341 791-A2	09-10-2003	3m Innovative Properties Co		
	B24	EP-1 495 758-A2	01-12-2005	3m Innovative Properties Co		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	5	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A77*	US-6,207,646	03-27-2001	Krieg <i>et al.</i>	
	A78*	US-6,239,116	05-29-2001	Krieg <i>et al.</i>	
	A79*	US-6,294,271	09-25-2001	Sumita <i>et al.</i>	
	A80*	US-6,303,347	10-16-2001	Johnson <i>et al.</i>	
	A81*	US-6,309,623	10-30-2001	Weers <i>et al.</i>	
	A82*	US-6,315,985	11-13-2001	Wu <i>et al.</i>	
	A83*	US-6,323,200	11-27-2001	Gerster <i>et al.</i>	
	A84*	US-6,329,381	12-11-2001	Kurimoto <i>et al.</i>	
	A85*	US-6,339,068	01-15-2002	Krieg <i>et al.</i>	
	A86*	US-6,348,462	02-19-2002	Gerster <i>et al.</i>	
	A87*	US-6,365,166	04-02-2002	Beaurline <i>et al.</i>	
	A88*	US-6,376,501	04-23-2002	Isobe <i>et al.</i>	
	A89*	US-6,387,383	05-14-2002	Dow <i>et al.</i>	
	A90*	US-6,387,938	05-14-2002	Mizuguchi <i>et al.</i>	
	A91*	US-6,406,705	06-18-2002	Davis <i>et al.</i>	
	A92*	US-6,426,334	07-30-2002	Agrawal <i>et al.</i>	
	A93*	US-6,440,992	08-27-2002	Gerster <i>et al.</i>	
	A94*	US-6,451,485	09-17-2002	James <i>et al.</i>	
	A95*	US-6,476,000	11-05-2002	Agrawal	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B25	HU-34479-A2	03-28-1985	Egyt Gyogyszervegyeszeti Gyar		✓
	B26	HU-210051-A2	06-28-1991	Riker Laboratories Inc		
	B27	HU-218950-A2	09-28-1995	Shionogi & Co		
	B28	IL-73534-A	12-23-1990	Riker Laboratories Inc		✓
	B29	JP-4066571-A	03-02-1992	Meiji Seika Kaisha		✓
	B30	JP-4327587-A	11-17-1992	Asahi Chemical Ind		✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	6	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A96*	US-6,486,168	11-26-2002	Skwirczynski <i>et al.</i>	
	A97*	US-6,486,186	11-26-2002	Fowler <i>et al.</i>	
	A98*	US-6,511,485	01-28-2003	Hirt <i>et al.</i>	
	A99*	US-6,514,985	02-04-2003	Gerster <i>et al.</i>	
	A100*	US-6,518,239	02-11-2003	Kuo <i>et al.</i>	
	A101*	US-6,518,280	02-11-2003	Gerster <i>et al.</i>	
	A102*	US-6,525,028	02-25-2003	Johnson <i>et al.</i>	
	A103*	US-6,582,957	06-24-2003	Turner, Jr. <i>et al.</i>	
	A104*	US-6,610,319	08-26-2003	Tomai <i>et al.</i>	
	A105*	US-6,627,638	09-30-2003	Gerster <i>et al.</i>	
	A106*	US-6,627,639	09-30-2003	Stack <i>et al.</i>	
	A107*	US-6,627,640	09-30-2003	Gerster <i>et al.</i>	
	A108*	US-6,630,588	10-07-2003	Rice <i>et al.</i>	
	A109*	US-6,638,944	10-28-2003	Mickelson	
	A110*	US-6,649,172	11-18-2003	Johnson	
	A111*	US-6,677,334	01-13-2004	Gerster <i>et al.</i>	
	A112*	US-6,696,076	02-24-2004	Tomai <i>et al.</i>	
	A113*	US-6,703,402	03-09-2004	Gerster <i>et al.</i>	
	A114*	US-6,716,988	04-06-2004	Dellaria <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
	B31	JP-5286973-A	11-02-1993	Shionogi & Co		✓
	B32	JP-53050197-A	05-08-1978	Yoshitomi Pharmaceutical		✓
	B33	JP-63010787-A	01-18-1988	Takeda Chemical Industries Ltd		✓
	B34	NZ-545412-A	12-24-2008	Coley Pharm Group Inc		
	B35	RU-2076105-C1	03-27-1997	Hoechst Ag		✓
	B36	RU-2127273-C1	03-10-1999	Janssen Pharmaceutica Nv		✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,959-Conf. #9672	
			Filing Date	May 22, 2006	
			First Named Inventor	Larry R. Krepski	
			Art Unit	1625	
			Examiner Name	R. J. Desai	
Sheet	7	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A115*	US-6,720,333	04-13-2004	Dellaria <i>et al.</i>	
	A116*	US-6,720,334	04-13-2004	Dellaria <i>et al.</i>	
	A117*	US-6,720,422	04-13-2004	Dellaria <i>et al.</i>	
	A118*	US-6,780,873	08-24-2004	Crooks <i>et al.</i>	
	A119*	US-6,784,188	08-31-2004	Crooks <i>et al.</i>	
	A120*	US-6,790,961	09-14-2004	Gerster <i>et al.</i>	
	A121*	US-6,800,624	10-05-2004	Crooks <i>et al.</i>	
	A122*	US-6,825,350	11-30-2004	Crooks <i>et al.</i>	
	A123*	US-6,855,217	02-15-2005	Suzuki	
	A124*	US-6,855,350	02-15-2005	Lu	
	A125*	US-6,878,719	04-12-2005	Lindstrom <i>et al.</i>	
	A126*	US-6,888,000	05-03-2005	Crooks <i>et al.</i>	
	A127*	US-6,894,060	05-17-2005	Slade	
	A128*	US-6,894,165	05-17-2005	Gerster <i>et al.</i>	
	A129*	US-6,897,221	05-24-2005	Crooks <i>et al.</i>	
	A130*	US-6,900,016	05-31-2005	Venter <i>et al.</i>	
	A131*	US-6,903,113	06-07-2005	Heppner <i>et al.</i>	
	A132*	US-6,916,925	07-12-2005	Rice <i>et al.</i>	
	A133*	US-6,921,826	07-26-2005	Dellaria <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B37	RU-2221798-C2	01-20-2004	Lingstrom <i>et al.</i>		<input checked="" type="checkbox"/>
	B38	WO-91/06682-A1	05-16-1991	Pfeifer & Langen		<input checked="" type="checkbox"/>
	B39	WO-92/06093-A1	04-16-1992	Minnesota Mining & Mfg		<input type="checkbox"/>
	B40	WO-92/15581-A1	09-17-1992	Minnesota Mining & Mfg		<input type="checkbox"/>
	B41	WO-92/15582-A1	09-17-1992	Minnesota Mining & Mfg		<input type="checkbox"/>
	B42	WO-93/05042-A1	03-18-1993	Minnesota Mining & Mfg		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,959-Conf. #9672	
			Filing Date	May 22, 2006	
			First Named Inventor	Larry R. Krepski	
			Art Unit	1625	
			Examiner Name	R. J. Desai	
Sheet	8	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A134*	US-6,924,293	08-02-2005	Lindstrom	
	A135*	US-6,943,240	09-13-2005	Bauer <i>et al.</i>	
	A136*	US-6,943,255	09-13-2005	Lindstrom <i>et al.</i>	
	A137*	US-6,949,649	09-27-2005	Bonk <i>et al.</i>	
	A138*	US-6,953,804	10-11-2005	Dellaria <i>et al.</i>	
	A139*	US-6,969,722	11-29-2005	Heppner <i>et al.</i>	
	A140*	US-6,989,389	01-24-2006	Heppner <i>et al.</i>	
	A141*	US-7,030,129	04-18-2006	Miller <i>et al.</i>	
	A142*	US-7,030,131	04-18-2006	Crooks <i>et al.</i>	
	A143*	US-7,038,053	05-02-2006	Lindstrom <i>et al.</i>	
	A144*	US-7,049,439	05-23-2006	Crooks <i>et al.</i>	
	A145*	US-7,078,253	07-18-2006	Brunner <i>et al.</i>	
	A146*	US-7,078,523	07-18-2006	Crooks <i>et al.</i>	
	A147*	US-7,098,221	08-29-2006	Heppner <i>et al.</i>	
	A148*	US-7,112,677	09-26-2006	Griesgraber	
	A149*	US-7,115,622	10-03-2006	Crooks <i>et al.</i>	
	A150*	US-7,125,890	10-24-2006	Dellaria <i>et al.</i>	
	A151*	US-7,132,429	11-07-2006	Griesgraber <i>et al.</i>	
	A152*	US-7,163,947	01-16-2007	Griesgraber <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B43	WO-93/09119-A1	05-13-1993	Minnesota Mining & Mfg		
	B44	WO-93/20847-A1	10-28-1993	Minnesota Mining & Mfg		
	B45	WO-94/10171-A1	05-11-1994	Pfizer <i>et al.</i>		
	B46	WO-95/02597-A1	01-26-1995	Minnesota Mining & Mfg		
	B47	WO-95/02598-A1	01-26-1995	Minnesota Mining & Mfg		
	B48	WO-96/11199-A1	04-18-1996	Knoll Ag <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	9	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A153*	US-7,179,253	02-20-2007	Graham <i>et al.</i>	
	A154*	US-7,199,131	04-03-2007	Lindstrom	
	A155*	US-7,214,675	05-08-2007	Griesgraber	
	A156*	US-7,220,758	05-22-2007	Dellaria <i>et al.</i>	
	A157*	US-7,226,928	06-05-2007	Mitra <i>et al.</i>	
	A158*	US-7,276,515	10-02-2007	Dellaria <i>et al.</i>	
	A159*	US-7,288,550	10-30-2007	Dellaria <i>et al.</i>	
	A160*	US-7,375,180	05-20-2008	Gorden <i>et al.</i>	
	A161*	US-7,387,271	06-17-2008	Noelle <i>et al.</i>	
	A162*	US-7,393,859	07-01-2008	Coleman <i>et al.</i>	
	A163*	US-7,427,629	09-23-2008	Kedl <i>et al.</i>	
	A164*	US-7,544,697	06-09-2009	Hays <i>et al.</i>	
	A165*	US-7,598,382	10-06-2009	Hays <i>et al.</i>	
	A166*	US-7,612,083	11-03-2009	Griesgraber	
	A167*	US-7,648,997	01-19-2010	Kshirsagar <i>et al.</i>	
	A168*	US-2001-0046968	11-29-2001	Zagon <i>et al.</i>	
	A169*	US-2002-0137101	09-26-2002	Meyers	
	A170*	US-2002-0173655	11-21-2002	Dellaria <i>et al.</i>	
	A171*	US-2002-0193729	12-19-2002	Cormier <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B49	WO-96/21663-A1	07-18-1996	Minnesota Mining & Mfg		
	B50	WO-97/48703-A1	12-24-1997	Minnesota Mining & Mfg		
	B51	WO-97/48704-A1	12-24-1997	Minnesota Mining & Mfg		
	B52	WO-98/17279-A1	04-30-1998	Minnesota Mining & Mfg		
	B53	WO-98/30562-A1	07-16-1998	Terumo Corp <i>et al.</i>		√
	B54	WO-98/48805-A1	11-05-1998	Sumitomo Pharma <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	10	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A172*	US-2003-0022302	01-30-2003	Lewis <i>et al.</i>	
	A173*	US-2003-0044429	03-06-2003	Aderem <i>et al.</i>	
	A174*	US-2003-0082108	05-01-2003	Mulshine <i>et al.</i>	
	A175*	US-2003-0088102	05-08-2003	Matsubara <i>et al.</i>	
	A176*	US-2003-0096998	05-22-2003	Gerster <i>et al.</i>	
	A177*	US-2003-0133733	07-17-2003	Korhonen	
	A178*	US-2003-0144283	07-31-2003	Coleman <i>et al.</i>	
	A179*	US-2003-0158192	08-21-2003	Crooks <i>et al.</i>	
	A180*	US-2003-0172391	09-11-2003	Turner <i>et al.</i>	
	A181*	US-2003-0185835	10-02-2003	Braun	
	A182*	US-2003-0187016	10-02-2003	Crooks <i>et al.</i>	
	A183*	US-2003-0199461	10-23-2003	Averett <i>et al.</i>	
	A184*	US-2003-0212092	11-13-2003	Heppner <i>et al.</i>	
	A185*	US-2003-0216481	11-20-2003	Jia	
	A186*	US-2003-0232074	12-18-2003	Lipford <i>et al.</i>	
	A187*	US-2003-0232763	12-18-2003	Jia	
	A188*	US-2003-0232852	12-18-2003	Lindstrom <i>et al.</i>	
	A189*	US-2004-0010007	01-15-2004	Dellaria <i>et al.</i>	
	A190*	US-2004-0023870	02-05-2004	Dedera <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY			
	B55	WO-98/50547-A2	11-12-1998	Schering Corp		
	B56	WO-98/54226-A1	12-03-1998	Pastoral Agric Res Inst Nz Ltd <i>et al.</i>		
	B57	WO-99/18105-A1	04-15-1999	Ortho Mcneil Pharm Inc		
	B58	WO-99/29693-A1	06-17-1999	Minnesota Mining & Mfg		
	B59	WO-00/06577-A1	02-10-2000	3m Innovative Properties Co		
	B60	WO-00/09506-A1	02-24-2000	Hokuriku Pharmaceutical <i>et al.</i>		✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	11	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A191*	US-2004-0067975	04-08-2004	Crooks <i>et al.</i>	
	A192*	US-2004-0072858	04-15-2004	Charles <i>et al.</i>	
	A193*	US-2004-0076633	04-22-2004	Thomsen <i>et al.</i>	
	A194*	US-2004-0092545	05-13-2004	Crooks <i>et al.</i>	
	A195*	US-2004-0097542	05-20-2004	Crooks <i>et al.</i>	
	A196*	US-2004-0106638	06-03-2004	Lindstrom	
	A197*	US-2004-0132748	07-08-2004	Isobe <i>et al.</i>	
	A198*	US-2004-0132766	07-08-2004	Griesgraber	
	A199*	US-2004-0157874	08-12-2004	Crooks <i>et al.</i>	
	A200*	US-2004-0167157	08-26-2004	Masui <i>et al.</i>	
	A201*	US-2004-0204436	10-14-2004	Gerster <i>et al.</i>	
	A202*	US-2004-0258698	12-23-2004	Wightman <i>et al.</i>	
	A203*	US-2004-0265351	12-30-2004	Miller <i>et al.</i>	
	A204*	US-2005-0009858	01-13-2005	Martinez-Colon <i>et al.</i>	
	A205*	US-2005-0032829	02-10-2005	Lindstrom <i>et al.</i>	
	A206*	US-2005-0048072	03-03-2005	Kedl <i>et al.</i>	
	A207*	US-2005-0054640	03-10-2005	Griesgraber <i>et al.</i>	
	A208*	US-2005-0054665	03-10-2005	Miller <i>et al.</i>	
	A209*	US-2005-0059072	03-17-2005	Birmachu <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B61	WO-00/19987-A1	04-13-2000	3m Innovative Properties Co <i>et al.</i>		
	B62	WO-00/40228-A2	07-13-2000	3m Innovative Properties Co		
	B63	WO-00/47719-A2	08-17-2000	3m Innovative Properties Co		
	B64	WO-00/75304-A1	12-14-2000	Aventis Pasteur <i>et al.</i>		y
	B65	WO-00/76505-A1	12-21-2000	3m Innovative Properties Co		
	B66	WO-00/76518-A1	12-21-2000	3m Innovative Properties Co		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	12	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A210*	US-2005-0096259	05-05-2005	Tomai <i>et al.</i>	
	A211*	US-2005-0119273	06-02-2005	Lipford <i>et al.</i>	
	A212*	US-2005-0136065	06-23-2005	Valiante	
	A213*	US-2005-0148620	07-07-2005	Crooks <i>et al.</i>	
	A214*	US-2005-0158325	07-21-2005	Hammerbeck <i>et al.</i>	
	A215*	US-2005-0171072	08-04-2005	Tomai <i>et al.</i>	
	A216*	US-2005-0226878	10-13-2005	Tomai <i>et al.</i>	
	A217*	US-2005-0234088	10-20-2005	Griesgraber	
	A218*	US-2005-0239733	10-27-2005	Jurk <i>et al.</i>	
	A219*	US-2005-0239735	10-27-2005	Miller <i>et al.</i>	
	A220*	US-2005-0267145	12-01-2005	Merrill <i>et al.</i>	
	A221*	US-2005-0281813	12-22-2005	Dedera <i>et al.</i>	
	A222*	US-2006-0009482	01-12-2006	Tomai <i>et al.</i>	
	A223*	US-2006-0100229	05-11-2006	Hays <i>et al.</i>	
	A224*	US-2006-0106052	05-18-2006	Crooks <i>et al.</i>	
	A225*	US-2007-0060754	03-15-2007	Lindstrom <i>et al.</i>	
	A226*	US-2007-0066639	03-22-2007	Kshirsagar <i>et al.</i>	
	A227*	US-2007-0099901	05-03-2007	Krepski <i>et al.</i>	
	A228*	US-2007-0155767	07-05-2007	Radmer <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B67	WO-00/76519-A1	12-21-2000	3m Innovative Properties Co		
	B68	WO-01/34709-A1	05-17-2001	3m Innovative Properties Co		
	B69	WO-01/51486-A2	07-19-2001	Byk Gulden Lomberg Chem Fab <i>et al.</i>		
	B70	WO-01/55439-A1	08-02-2001	Progenics Pharm Inc		
	B71	WO-01/58900-A1	08-16-2001	Hokuriku Pharmaceutical <i>et al.</i>		v
	B72	WO-01/74343-A2	10-11-2001	3m Innovative Properties Co		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	13	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A229*	US-2007-0167476	07-19-2007	Kshirsagar <i>et al.</i>	
	A230*	US-2007-0208052	09-06-2007	Prince <i>et al.</i>	
	A231*	US-2007-0213356	09-13-2007	Merrill <i>et al.</i>	
	A232*	US-2007-0219196	09-20-2007	Krepski <i>et al.</i>	
	A233*	US-2007-0219228	09-20-2007	Niwas <i>et al.</i>	
	A234*	US-2007-0259881	11-08-2007	Dellaria <i>et al.</i>	
	A235*	US-2007-0259907	11-08-2007	Prince	
	A236*	US-2007-0287725	12-13-2007	Miser <i>et al.</i>	
	A237*	US-2008-0015184	01-17-2008	Kshirsagar <i>et al.</i>	
	A238*	US-2008-0070907	03-20-2008	Griesgraber <i>et al.</i>	
	A239*	US-2008-0085895	04-10-2008	Griesgraber <i>et al.</i>	
	A240*	US-2008-0114019	05-15-2008	Kshirsagar <i>et al.</i>	
	A241*	US-2008-0119508	05-22-2008	Slade <i>et al.</i>	
	A242*	US-2008-0207674	08-28-2008	Stoesz <i>et al.</i>	
	A243*	US-2008-0269192	10-30-2008	Griesgraber <i>et al.</i>	
	A244*	US-2008-0306252	12-11-2008	Crooks <i>et al.</i>	
	A245*	US-2008-0312434	12-18-2008	Lindstrom <i>et al.</i>	
	A246*	US-2008-0318998	12-25-2008	Prince <i>et al.</i>	
	A247*	US-2009-0005371	01-01-2009	Rice <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B73	WO-01/74821-A1	10-11-2001	Shionogi & Co <i>et al.</i>		✓
	B74	WO-02/07725-A1	01-31-2002	Alteon Inc		
	B75	WO-02/22809-A2	03-21-2002	Coley Pharm Gmbh <i>et al.</i>		
	B76	WO-02/24225-A1	03-28-2002	Glaxo Group Ltd <i>et al.</i>		
	B77	WO-02/46188-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B78	WO-02/46189-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	14	of	58	Attorney Docket Number	C1271.70022US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A248*	US-2009-0017076	01-15-2009	Miller <i>et al.</i>	
	A249*	US-2009-0018122	01-15-2009	Lindstrom <i>et al.</i>	
	A250*	US-2009-0023722	01-22-2009	Coleman <i>et al.</i>	
	A251*	US-2009-0029988	01-29-2009	Kshirsagar <i>et al.</i>	
	A252*	US-2009-0030030	01-29-2009	Bonk <i>et al.</i>	
	A253*	US-2009-0030031	01-29-2009	Kshirsagar <i>et al.</i>	
	A254*	US-2009-0042925	02-12-2009	Kshirsagar <i>et al.</i>	
	A255*	US-2009-0062272	03-05-2009	Bonk <i>et al.</i>	
	A256*	US-2009-0062328	03-05-2009	Kshirsagar <i>et al.</i>	
	A257*	US-2009-0069299	03-12-2009	Merrill <i>et al.</i>	
	A258*	US-2009-0069314	03-12-2009	Kshirsagar <i>et al.</i>	
	A259*	US-2009-0075980	03-19-2009	Hays <i>et al.</i>	
	A260*	US-2009-0099161	04-16-2009	Rice <i>et al.</i>	
	A261*	US-2009-0105295	04-23-2009	Kshirsagar <i>et al.</i>	
	A262*	US-2009-0124611	05-14-2009	Hays <i>et al.</i>	
	A263*	US-2009-0163533	06-25-2009	Hays <i>et al.</i>	
	A264*	US-2009-0176821	07-09-2009	Kshirsagar <i>et al.</i>	
	A265*	US-2009-0240055	09-24-2009	Krepski <i>et al.</i>	
	A266*	US-2009-0253695	10-08-2009	Kshirsagar <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
	B79	WO-02/46190-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B80	WO-02/46191-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B81	WO-02/46192-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B82	WO-02/46193-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B83	WO-02/46194-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B84	WO-02/46749-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	19	of	58	Attorney Docket Number	C1271.70022US02

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B109	WO-2004/053057-A2	06-24-2004	3m Innovative Properties Co		
	B110	WO-2004/053452-A2	06-24-2004	3m Innovative Properties Co		
	B111	WO-2004/058759-A1	07-15-2004	3m Innovative Properties Co		
	B112	WO-2004/071459-A2	08-26-2004	3m Innovative Properties Co <i>et al.</i>		
	B113	WO-2004/075865-A2	09-10-2004	3m Innovative Properties Co		
	B114	WO-2004/080398-A2	09-23-2004	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	21	of	58	Attorney Docket Number	C1271.70022US02

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		
	B121	WO-2005/023190-A2	03-17-2005	3m Innovative Properties Co	
	B122	WO-2005/025614-A2	03-24-2005	Glaxo Group Ltd <i>et al.</i>	
	B123	WO-2005/029037-A2	03-31-2005	3m Innovative Properties Co	
	B124	WO-2005/041891-A2	05-12-2005	3m Innovative Properties Co	
	B125	WO-2005/049076-A1	06-02-2005	Ct Ingenieria Genetica Biotech <i>et al.</i>	
	B126	WO-2005/065678-A1	07-21-2005	3m Innovative Properties Co	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
				Attorney Docket Number	C1271.70022US02
Sheet	22	of	58		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B127	WO-2005/067500-A2	07-28-2005	3m Innovative Properties Co		
	B128	WO-2005/110013-A2	11-24-2005	3m Innovative Properties Co <i>et al.</i>		
	B129	WO-2006/063072-A2	06-15-2006	3m Innovative Properties Co <i>et al.</i>		
	B130	WO-2006/063152-A2	06-15-2006	3m Innovative Properties Co <i>et al.</i>		
	B131	WO-2006/073940-A2	07-13-2006	3m Innovative Properties Co <i>et al.</i>		
	B132	WO-2006/074045-A2	07-13-2006	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>3</sup> Applicant's unique citation designation number (optional). <sup>4</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>5</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>7</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

2052366.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	27	of	58	Attorney Docket Number	C1271.70022US02

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B157	WO-2007/079171-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B158	WO-2007/079202-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B159	WO-2007/079203-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B160	WO-2007/092641-A2	08-16-2007	3m Innovative Properties Co <i>et al.</i>		
	B161	WO-2007/106852-A2	09-20-2007	3m Innovative Properties Co <i>et al.</i>		
	B162	WO-2007/106854-A2	09-20-2007	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and (\*) not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
				Attorney Docket Number	C1271.70022US02
Sheet	28	of	58		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	MM-DD-YYYY			
	B163	WO-2007/120121-A2	10-25-2007	Coley Pharm Group Inc <i>et al.</i>		
	B164	WO-2007/143526-A2	12-13-2007	Coley Pharm Group Inc <i>et al.</i>		
	B165	WO-2008/008432-A2	01-17-2008	Coley Pharm Group Inc <i>et al.</i>		
	B166	WO-2008/030511-A2	03-13-2008	Coley Pharmaceutical Group In <i>et al.</i>		
	B167	WO-2008/036312-A1	03-27-2008	Coley Pharm Group Inc <i>et al.</i>		
	B168	WO-2008/045543-A1	04-17-2008	Coley Pharm Group Inc <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	29	of	58	Attorney Docket Number	C1271.70022US02

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	29	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Supplementary Partial European Search Report for EP 04812098.4 mailed May 15, 2009 (C1271.70022EP00).	
	C2	International Search Report and Written Opinion for PCT/US2004/039512 mailed March 29, 2006 (C1271.70022WO00).	
	C3	International Preliminary Report on Patentability for PCT/US2004/039512 mailed June 8, 2006 (C1271.70022WO00).	
	C4	[NO AUTHOR LISTED] "Comparative Tests." Filed April 8, 2005 during prosecution for EP 00938205.2, EP 00950215.4 and EP 00938211.0 in the name of 3M Innovative Properties Co.	
	C5	[NO AUTHOR LISTED] Chemical Abstracts. 1964;61(1):6060g.	
	C6	[NO AUTHOR LISTED] Encyclopedia of Pharmaceutical Technology. 2nd Ed. Marcel Dekker, Inc. 2002:856-60.	
	C7	AGRAWAL <i>et al.</i> , Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7.	
	C8	AHMED <i>et al.</i> , A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994 Apr 15;170(2):211-24.	
	C9	AKIRA <i>et al.</i> , Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2001;2(8):675-80	
	C10	AKIRA <i>et al.</i> , Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85-95.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	30	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C11	ALEXOPOULOU <i>et al.</i> , Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. <i>Nature</i> . 2001 Oct 18;413(6857):732-8.		
	C12	ASSUMA <i>et al.</i> , IL-1 and TNF Antagonists Inhibit the Inflammatory Response and Bone Loss in Experimental Periodontitis. <i>J Immunol</i> . 2000;160:403-09.		
	C13	AU <i>et al.</i> , Virus-mediated induction of interferon A gene requires cooperation between multiple binding factors in the interferon alpha promoter region. <i>J Biol Chem</i> . 1993 Nov 15;268(32):24032-40.		
	C14	AUERBACH <i>et al.</i> , Erythema nodosum following a jellyfish sting. <i>J Emerg Med</i> . 1987 Nov-Dec;5(6):487-91.		
	C15	AUWERS, [Über die Isomerie-Verhältnisse in der Pyrazol-Reihe. <i>Berichte</i> . VI.] 1926;601-607. German		
	C16	BAFFIS <i>et al.</i> , Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. <i>Ann Intern Med</i> . 1999 Nov 2;131(9):696-701.		
	C17	BAKER <i>et al.</i> , Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. <i>Arch Oral Biol</i> . 1994 Dec;39(12):1035-40.		
	C18	BALDWIN <i>et al.</i> , Amino Acid Synthesis via Ring Opening of N-Sulphonyl Aziridine-2-Carboxylate Esters with Organometallic Reagents. <i>Tetrahedron</i> . 1993;49:6309-30.		
	C19	BÁRTOVÁ <i>et al.</i> , Th1 and Th2 cytokine profile in patients with early onset periodontitis and their healthy siblings. <i>Mediators Inflamm</i> . 2000;9(2):115-20.		
	C20	BECK <i>et al.</i> , Dental Infections and Atherosclerosis. <i>Am Heart J</i> . 1999;13:528-33.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	31	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C21	BECKETT <i>et al.</i> , Configurational Studies in Synthetic Analgesics: the Synthesis of (-)-Methadone from D-(-)- Alanine. J Chem Soc. 1957;1:858-61.	
	C22	BELLMAN <i>et al.</i> , Experimental brown spider bite in the guinea pig: Results of treatment with dapsone or hyperbaric oxygen. J Wilderness Medicine. 1994;5:287-94.	
	C23	BELIKOV, Abbreviated Guide to Synthetic and Natural Medications. Pharmaceutical Chemistry. Higher School. 1993;1:43-47. Russian.	√
	C24	BELTRAMI <i>et al.</i> , Some Methylhydrazonium Salts; An Improved Synthesis of Tetramethylhydrazine. J Am Chem Soc. 1956;78:2467-68.	
	C25	BERNSTEIN <i>et al.</i> , Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis. 2001 Mar 15;183(6):844-9. Epub 2001 Feb 13.	
	C26	BERTINO <i>et al.</i> , Principles of Cancer Therapy. Cecil Textbook of Medicine. Goldman <i>et al.</i> , eds. 21th Ed. W.B. Saunders Company. 2000:1:1060-74.	
	C27	BEUTLER <i>et al.</i> , Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med. 1993 Oct;21(10 Suppl):S423-35.	
	C28	BEUTNER <i>et al.</i> , Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002-7.	
	C29	BEUTNER <i>et al.</i> , Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9.	
	C30	BINDER, Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp. 1989 May-Jun;4(3):163-73.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	32	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	BISHOP <i>et al.</i> , Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol. 2000 Nov 15;165(10):5552-7.	
	C32	BITTERMAN-DEUTSCH <i>et al.</i> , [Brown spider bite]. Harefuah. 1990 Sep;119(5-6):137-9. Hebrew.	√
	C33	BOOTH <i>et al.</i> , Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992 Feb;98(2):135-40.	
	C34	BORKAN <i>et al.</i> , An outbreak of venomous spider bites in a citrus grove. Am J Trop Med Hyg. 1995 Mar;52(3):228-30.	
	C35	BOURKE <i>et al.</i> , The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003 Aug 1;102(3):956-63. Epub 2003 Apr 10.	
	C36	BRANTS, The Distribution of Tobacco Mosaic Virus (TMV) in Excised Tomato Roots Cultivated in Vitro. Tijdschr Plantenziekten, 1962;68:198-207.	
	C37	BRASSARD <i>et al.</i> , Interferon-α as an immunotherapeutic protein. J Leukoc Biol. 2002 Apr;71(4):565-81.	
	C38	BREATHNACH, Azelaic acid: potential as a general antitumoural agent. Med Hypotheses. 1999 Mar;52(3):221-6.	
	C39	BROUGHTON, Management of the brown recluse spider bite to the glans penis. Mil Med. 1996 Oct;161(10):627-9.	
	C40	BUCKLE <i>et al.</i> , 4-hydroxy-3-nitro-2-quinolones and related compounds as inhibitors of allergic reactions. J Med Chem. 1975 Jul;18(7):726-32.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	33	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C41	BUISSON <i>et al.</i> , Preparation and use of (S)-O-acetyllactyl chloride (Mosandl's reagent) as a chiral derivatizing agent. Tetrahedron Assym. 1999;10:2997-3002.		
	C42	BULUT <i>et al.</i> , Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol. 2001 Jul 15;167(2):987-94.		
	C43	BURLESON, Chapter 14. Influenza Virus Host Resistance Model for Assessment of Immunostimulation, and Antiviral Compounds. Methods in Immunology. 1995;2:181-202.		
	C44	BUSCHLE <i>et al.</i> , Interferon $\gamma$ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993 Jan 1;177(1):213-8.		
	C45	CAI <i>et al.</i> , Evaluation of trifluoroacetic acid as an ion-pair reagent in the separation of small ionizable molecules by reversed-phase liquid chromatography. Analytica Chmica Acta. 1999;399:249-258.		
	C46	CANTELL <i>et al.</i> , IFN- $\gamma$ Enhances Production of IFN- $\alpha$ in Human Macrophages but Not in Monocytes. J Interferon and Cytokine Res. 1996;16:461-63.		
	C47	CARCELLER <i>et al.</i> , Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. J Med Chem. 1996 Jan 19;39(2):487-93.		
	C48	CARRIGAN <i>et al.</i> , Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. J Med Chem. 2002 May 23;45(11):2260-76.		
	C49	CATARZI <i>et al.</i> , Tricyclic heteroaromatic systems. Pyrazolo[3,4-c]quinolin-4-ones and pyrazolo[3,4-c]quinoline-1,4-diones: synthesis and benzodiazepine receptor activity. Arch Pharm (Weinheim). 1997 Dec;330(12):383-6.		
	C50	CHESON <i>et al.</i> , National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	34	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C51	CHUANG <i>et al.</i> , Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002 Mar;71(3):538-44.		
	C52	CLAISEN, [Uber $\alpha$ -Methyl-isoxazol.] Berichte. 1909;42:59-69. German.		
	C53	COHEN <i>et al.</i> , Cytokine function: a study in biologic diversity. Am J Clin Pathol. 1996 May;105(5):589-98.		
	C54	COLE <i>et al.</i> , Brown recluse spider envenomation of the eyelid: an animal model. Ophthal Plast Reconstr Surg. 1995 Sep;11(3):153-64.		
	C55	COLOTTA <i>et al.</i> , Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem. 2000 Aug 10;43(16):3118-24.		
	C56	CRISTALLI <i>et al.</i> , Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem. 1991 Mar;34(3):1187-92.		
	C57	DAI <i>et al.</i> , Synthesis of a novel C2-symmetric thiourea and its application in the Pd-catalyzed cross-coupling reactions with arenediazonium salts under aerobic conditions. Org Lett. 2004 Jan 22;6(2):221-4.		
	C58	DAVIS, Current therapy for chronic hepatitis C. Gastroenterology. 2000 Feb;118(2 Suppl 1):S104-14.		
	C59	DAVIS <i>et al.</i> , Heterocyclic Syntheses with Malonyl Chloride. Part VI. 3-Substituted Pyridine Derivatives from $\alpha$ -Methylene-nitriles. J Chem Soc. 1962:3638-44.		
	C60	DAVIS <i>et al.</i> , Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med. 2000 Aug;45(8):619-23.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	35	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C61	DE <i>et al.</i> , Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem. 1998 Dec 3;41(25):4918-26.	
	C62	DEBOL <i>et al.</i> , Anti-inflammatory action of dapson: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997 Dec;62(6):827-36.	
	C63	DE CLERQ, Synthetic interferon inducers. Top Curr Chem. 1974;52:173-208.	
	C64	DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000 Feb 1;95(3):999-1006.	
	C65	DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol. 2000 May;28(5):558-68.	
	C66	DELGADO, Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ninth Edition, Remers, ed., 1991:30-1.	
	C67	DENZEL <i>et al.</i> Imidazo [4,5-c]- and [4,5-b]pyridines. J. Heterocyclic Chem. 1977;14:813-821.	
	C68	DIAZ-ARRASTIA <i>et al.</i> , Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res. 2001 Oct;7(10):3031-3.	
	C69	DI CARLO <i>et al.</i> , Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res. 2001 Dec;10(6):739-48.	
	C70	DICKEN <i>et al.</i> , Reactions at High Pressures. [3 + 2] Dipolar Cycloaddition of Nitrones with Vinyl Ethers. J Org Chem. 1982;47:2047-51.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	36	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C71	DOCKRELL <i>et al.</i> , Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001 Dec;48(6):751-5.		
	C72	DORWALD, "Preface." Side Reactions in Organic Synthesis. A Guide to Successful Synthesis Design. Wiley-VCH. 2005: IX.		
	C73	DOUGLAS, Introduction to Viral Diseases. In: Cecil Textbook of Medicine. Bennet <i>et al.</i> , eds. 20th Ed. W.B. Saunders Company. 1996:2:1739-47.		
	C74	DOYLE <i>et al.</i> , Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol. 2003 Apr 1;170(7):3565-71.		
	C75	DREXLER <i>et al.</i> , Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood. 1989 Oct;74(5):1747-57.		
	C76	DZIOANEK <i>et al.</i> BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000 Dec 1;165(11):6037-46.		
	C77	EDWARDS <i>et al.</i> , Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol. 2003 Apr;33(4):827-33.		
	C78	ERIKS <i>et al.</i> , Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles. J Med Chem. 1992 Aug 21;35(17):3239-46.		
	C79	FECCI <i>et al.</i> , The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003 Aug-Sep;64(1-2):161-76.		
	C80	FITZGERALD-BOCARSLY <i>et al.</i> , Virally-Responsive IFN- $\alpha$ Producing Cells in Human Blood and Tonsil Are CD11C/CD123+ Cells Identical to Precursors of Type Two Dendritic Cells (pDC2). J Interferon Cytokine Res. 1999;19(1):S117. Abstract P81.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	37	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C81	FLO <i>et al.</i> , Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002 Sep 20;277(38):35489-95. Epub 2002 Jun 27.		
	C82	FONTENEAU <i>et al.</i> , Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells. J Virol. 2004;78(10):5223-32.		
	C83	FRANKEL <i>et al.</i> , The Preparation of N-Disubstituted Formamides. Tetrahedron Lett. 1959;7:5-7.		
	C84	FRANTZ <i>et al.</i> , Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999 Aug;104(3):271-80.		
	C85	FU <i>et al.</i> , Regioselective Catalytic Hydrogenation of Polycyclic Aromatic Hydrocarbons under Mild conditions. J Org Chem. 1980;45:2979-803.		
	C86	FUCHSBERGER <i>et al.</i> , Priming Interferon- $\alpha$ 1 or Interferon- $\alpha$ 2 Enhances the Production of Both Subtypes Simultaneously. J Interferon and Cytokine Res. 1995;15:637-39.		
	C87	GALOSE, DAPSONE (diaminodiphenylsulphone DDS). Clinical Toxicology Review. 1999;21(9). 3 pages.		
	C88	GENDRON, Loxosceles ignali Envenomation. Am J Emerg Med. 1990 Jan;8(1):51-4.		
	C89	GENEVOIS-BORELLA <i>et al.</i> , Synthesis of 1-(3-R-Amino-4-Hydroxy Butyl)thymine Acyclonucleoside. Analogs as Potential Anti-AIDS Drugs. Tetrahedron Lett. 1990;31:4879-82.		
	C90	GIANNINI <i>et al.</i> , Influence of the Mucosal Epithelium Microenvironment on Langerhans Cells: Implications for the Development of Squamous Intraepithelial Lesions of the Cervix. Int J Cancer. 2002;97:654-59.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	38	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C91	GIBSON <i>et al.</i> , Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res. 1995 Jun;15(6):537-45.		
	C92	GIBSON <i>et al.</i> , Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.		
	C93	GITELSON <i>et al.</i> , Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res. 2003 May;9(5):1656-65.		
	C94	GOMEZ <i>et al.</i> , Intradermal anti-Ixosceles Fab fragments attenuate dermonecrotic arachnidism. Acad Emerg Med. 1999;6:1195-202.		
	C95	GORDEN <i>et al.</i> , Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 Feb 1;174(3):1259-68.		
	C96	GORDON, Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002 Dec 27;111(7):927-30.		
	C97	GUNNING <i>et al.</i> , Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.		
	C98	GÜRSEL <i>et al.</i> , Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20.		
	C99	HART, Napthyridines Hydroxynapthyridies, Journal of Chemical Society, 1956;Part III:212-4.		
	C100	HARTMANN <i>et al.</i> , Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,959-Conf. #9672	
			Filing Date	May 22, 2006	
			First Named Inventor	Larry R. Krepski	
			Art Unit	1625	
			Examiner Name	R. J. Desai	
Sheet	39	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C101	HAYASHI Toll-like receptors stimulate human neutrophil function. Blood. 2003 Oct 1;102(7):2660-9. Epub 2003 Jun 26.	
	C102	HAYES <i>et al.</i> , Regulation of Interferon Production by Human Monocytes: Requirements for Priming for Lipopolysaccharide-Induced Production. J Leukocyte Biol. 1991;50:176-81.	
	C103	HEIL <i>et al.</i> , Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526-9. Epub 2004 Feb 19.	
	C104	HEIL <i>et al.</i> , Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8. 33th Annual Meeting of the Deutsche Gesellschaft für Immunologie, Marburg 2002. Abstract C.6.	
	C105	HEMMI <i>et al.</i> , Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22.	
	C106	HOBBS <i>et al.</i> , Comparison of hyperbaric oxygen and dapson therapy for loxosceles envenomation. Acad Emerg Med. 1996 Aug;3(8):758-61.	
	C107	HOFFMAN <i>et al.</i> , Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidine. J Med Chem. 1983 Feb;26(2):140-4.	
	C108	HOFMANOVÁ <i>et al.</i> , Lipxygenase inhibitors induce arrest of tumor cells in S-phase of the cell cycle. Neoplasma. 2002;49(6):362-7.	
	C109	HOLLADAY <i>et al.</i> , Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802.	
	C110	HORNG <i>et al.</i> , The adaptor molecule TIRAP provides signaling specificity for Toll-like receptors. Nature. 2002 Nov 21;420(6913):329-33.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	40	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C111	HORNUNG <i>et al.</i> , Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. Journal of Immunol. 2002;168:4531-37.		
	C112	HOUBEN-WEYL, Quinoline and Isoquinoline. Methoden der Organischen Chemie. 1980:271-79. German.	✓	
	C113	HOUSTON <i>et al.</i> , Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 8. Molecular dissections of carbocyclic 3-deazaadenosine as inhibitors of S-adenosylhomocysteine hydrolase. J Med Chem. 1985 Apr;28(4):467-71.		
	C114	HUPPATZ, Systemic fungicides. The synthesis of certain pyrazole analogues of carboxin. Aust J Chem. 1983;36:135-47.		
	C115	IINO <i>et al.</i> , Treatment of Chronic Hepatitis C With High-Dose Interferon α-2b. Multicenter Study. Dig Dis Sci. 1993;38(4):612-18.		
	C116	ITO <i>et al.</i> , Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002 Jun 3;195(11):1507-12.		
	C117	IWASHITA <i>et al.</i> , Syntheses of Isoretronecanol and Lupinine. J Org Chem. 1982;47:230-33.		
	C118	JACOBS, The Synthesis of Acetylenes. In: Organic Reactions. New York: Wiley & Sons, Inc., 1949. Volume 5. 1-78.		
	C119	JAHNSEN <i>et al.</i> , Extensive recruitment of IL-3Rα high dendritic-cell precursors to allergic nasal mucosa during allergen challenge. Immunology Lett. 1999;69(1):123. Abstract #32.2.		
	C120	JURK <i>et al.</i> Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002 Jun;3(6):499.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	41	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C121	JUWEID, Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice. J Nuclear Med. 2002;43(11):1507-29.	
	C122	KATRITSKY <i>et al.</i> , Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds. 1984;2:586-587.	
	C123	KEATING <i>et al.</i> , Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 1;81(11):2878-84.	
	C124	KLAUSEN <i>et al.</i> , Two complementary methods of assessing periodontal bone level in rats. Scand J Dent Res. 1989 Dec;97(6):494-9.	
	C125	KLINMAN, Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58.	
	C126	KLOEK <i>et al.</i> , An improved method for the synthesis of stabilized primary enamines and imines. J Org Chem. 1978;43:1460-62.	
	C127	KLOETZEL, Reactions of nitroparaffins. I. Synthesis and reduction of some o -nitrokenes. J Am Chem Soc. 1947;69:2271-2275.	
	C128	KORNMAN, Host modulation as a therapeutic strategy in the treatment of periodontal disease. Clin Infect Dis. 1999 Mar;28(3):520-6.	
	C129	KOURAFALOS <i>et al.</i> , Synthesis of 7-aminopyrazolo[3,4-c]pyridine as a probe for the preparation of compounds of pharmacological interest. Heterocycles. 2002;57(12):2335-2343.	
	C130	KRAUSE <i>et al.</i> , Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003 Oct 1;115(5):390-7.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	42	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C131	KRENITSKY <i>et al.</i> , Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and anti-inflammatory agents. J Med Chem. 1986 Jan;29(1):138-43.	
	C132	KURT-JONES <i>et al.</i> , Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood. 2002 Sep 1;100(5):1860-8.	
	C133	LALL <i>et al.</i> , Serine and threonine beta-lactones: a new class of hepatitis A virus 3C cysteine proteinase inhibitors. J Org Chem. 2002 Mar 8;67(5):1536-47.	
	C134	LEE <i>et al.</i> , p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther. 1999;82:389-97.	
	C135	LEE <i>et al.</i> , Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem. 2004 Apr 23;279(17):16971-9. Epub 2004 Feb 13.	
	C136	LEHNER <i>et al.</i> , The role of $\gamma\delta$ cells and $\beta$ -chemokines in mucosal protection against SIV infection. Immunology Lett. 1999;69:25-192. Abstract 2.1	
	C137	LEVY <i>et al.</i> , Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood. 2006 Aug 15;108(4):1284-90. Epub 2006 Apr 25.	
	C138	LEYNADIER <i>et al.</i> , Allergic reactions to North African scorpion venom evaluated by skin test and specific IgE. J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):851-3. 4 pages.	
	C139	LI <i>et al.</i> , An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids. J Org Chem. 2002 Jul 26;67(15):5394-7.	
	C140	LI <i>et al.</i> , Solubility behavior of imiquimod in alkanolic acids. Pharmaceutical Research. 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3029.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	43	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C141	LI <i>et al.</i> , Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1999 Feb 25;42(4):706-21.	
	C142	LITT <i>et al.</i> , Mucosal delivery of vaccine antigens displayed on the surface of Lactococcus lactis. Immunology Lett. 1999;69(1):61. Abstract #11.26.	
	C143	LIU <i>et al.</i> , Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents. Nucleosides Nucleotides Nucleic Acids. 2001 Dec;20(12):1975-2000.	
	C144	LOESCHE <i>et al.</i> , Treatment paradigms in periodontal disease. Compend Contin Educ Dent. 1997 Mar;18(3):221-6, 228-30, 232 passim; quiz 234. Review.	
	C145	LUGER <i>et al.</i> , Evidence for an epidermal cytokine network. J Invest Dermatol. 1990 Dec;95(6 Suppl):100S-104S.	
	C146	LUSKIN <i>et al.</i> , Olefinic Derivatives of 2,4-Diamino-s-triazines. J Org Chem. 1958;23:1032-37.	
	C147	MACCHIA <i>et al.</i> , Synthesis and antiviral properties of 9-[(2-methyleneaminoxymethoxy)methyl]guanine derivatives as novel Acyclovir analogues. Farmaco. 2000 Feb;55(2):104-8.	
	C148	MAJESKI <i>et al.</i> , Action of venom from the brown recluse spider ( <i>Loxosceles reclusa</i> ) on human neutrophils. Toxicon. 1977;15(5):423-7.	
	C149	MAKARENKOVA <i>et al.</i> , Identification of delta- and mu- type opioid receptors on human and murine dendritic cells. J Neuroimmunol. 2001;117:68-77.	
	C150	MALE <i>et al.</i> , Introduction to the Immune System. In: Immunology. Elsevier. 2006:6-7.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	44	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C151	MASIHI, Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases. Expert Opin Ther Patents. 2003;13(6):867-82.		
	C152	MASIUKIEWICZ <i>et al.</i> , Scalable Syntheses of N <sup>6</sup> -Benzyloxycarbonyl-L-Ornithine and of N <sup>6</sup> -(9-Fluorenylmethoxy)Carbonyl-L-Ornithine. Org Prep Proced Int. 2002;34:531-37.		
	C153	MATAKA <i>et al.</i> , Condensation reaction of 3,4-Dibenzoyl-1-methyl-2,5-diphenylpyrrole and -1-phenylpyrazole with methylamine derivatives affording pyrrolo [3,4-c] pyridine and 2H-pyrazolo[3,4-c]- and [4,3-c]pyridines. Journal of Heterocyclic Chemistry. 1981;18(6):1073-5.		
	C154	MATHUR <i>et al.</i> , Cell-mediated immune system regulation in periodontal diseases. Crit Rev Oral Biol Med. 1997;8(1):76-89.		
	C155	MAYNOR <i>et al.</i> , Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med. 1997 Mar;4(3):184-92.		
	C156	MBOW <i>et al.</i> , Small molecule and biologic modulators of the immune response to hepatitis C virus. Mini Rev Med Chem. 2006 May;6(5):527-31.		
	C157	MCCARTHY <i>et al.</i> , Opioids, opioid receptors, and the immune response. Drug & Alcohol Dependence. 2001;62:111-23.		
	C158	MCKENNON <i>et al.</i> , A Convenient Reduction of Amino Acids and Their Derivatives. J Org Chem. 1993;58:3568-71.		
	C159	MCLAUGHLIN <i>et al.</i> , Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett. 2003;199:209-17.		
	C160	MEDZHITOV, Toll-Like Receptors and Innate Immunity. Nature Rev Immunol. 2001;1:135-45.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	45	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C161	MEE <i>et al.</i> , Stille coupling made easier - the synergic effect of copper(I) salts and the fluoride ion. <i>Angew Chem.</i> 2004;116:1152-56.	
	C162	MERIGIAN <i>et al.</i> , Envenomation From the Brown Recluse Spider: Review of Mechanism and Treatment Options. <i>Am J Ther.</i> 1996 Oct;3(10):724-734.	
	C163	MILLER <i>et al.</i> , Imiquimod applied topically: a novel immune response modifier and new class of drug. <i>Int J Immunopharmacol.</i> 1999 Jan;21(1):1-14.	
	C164	MINAKAWA <i>et al.</i> , Nucleosides and Nucleotides. 184. Synthesis and Conformational Investigation of Anti-Fixed 3-Deaza-3-halopurine Ribonucleosides. <i>J Org Chem.</i> 1999;64:7158-72.	
	C165	MOEBIUS <i>et al.</i> , The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. <i>Trends Pharmacol Sci.</i> 1997 Mar;18(3):67-70.	
	C166	MOLDOVEANU <i>et al.</i> , Poly-L-lysine as a potential mucosal adjuvant. <i>Immunology Lett.</i> 1999;69(1):62. Abstract #11.28.	
	C167	MOLLICK <i>et al.</i> , MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. <i>Cancer Immun.</i> 2003 Mar 17;3:3. 17 pages.	
	C168	MOODY <i>et al.</i> , Lipxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. <i>Exp Lung Res.</i> 1998 Jul-Aug;24(4):617-28.	
	C169	MORACZEWSKI <i>et al.</i> , Using Hydrogen Bonding to Control Carbamate C-N Rotamer Equilibria. <i>Org Chem.</i> 1998 Oct 16;63(21):7258-7262.	
	C170	MOSBECH <i>et al.</i> , [Allergy to insect stings] <i>Ugeskr Laeger.</i> 1991 Oct 28;153(44):3067-71. Danish.	✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	46	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C171	MUCHE <i>et al.</i> , Imiquimod treatment of cutaneous T cell lymphoma. Journal of Investigative Dermatology. 2003 July;121(1):0975. Joint Meeting of the European Society for Dermatology; Miami Beach, Florida, USA. April 30-May 04, 2003. Abstract 0975.		
	C172	MULLER <i>et al.</i> , An improved one-pot procedure for the synthesis of alkynes from aldehydes. Synlett. 1996;6:521-522.		
	C173	MUTSCHLER <i>et al.</i> , 9.2 Anti-infectives. In: Drug Actions: Basic Principles and Therapeutic Aspects. 1995:515-80.		
	C174	MUZIO <i>et al.</i> , Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000 Jun 1;164(11):5998-6004.		
	C175	NAGARAJAN <i>et al.</i> , Condensed heterotricycles: synthesis of pyrazolo[3,4-c]quinoline derivatives. Indian Journal of Chemistry. 1992;31B:316-321.		
	C176	NAGASE <i>et al.</i> , Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003 Oct 15;171(8):3977-82.		
	C177	NANJAPPAN <i>et al.</i> , An efficient synthesis of some 6-substituted 4,8-diaza-3,3,9,9-tetramethylundeca-2,10-dione dioximes (propylene amine oximes, PnAOs): Ligands for 99mTc complexes used in structure distribution relationship (SDR) studies. Tetrahedron. 1994;50(29):8617-32.		
	C178	OHANA <i>et al.</i> , Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. Journal of Cellular Physiology. 2001 Jan;186(1):19-23. Review.		
	C179	O'MAHONY <i>et al.</i> , New patient-applied therapy for anogenital warts is rated favourably by patients. Intl J STD & AIDS. 2001;12:565-70.		
	C180	OSOL <i>et al.</i> , Chapter 27: Structure-Activity Relationship and Drug Design. In: Remington's Pharmaceutical Sciences. 16th Ed. Mach Publishing. 1980:420-35.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	47	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C181	OTTONELLO <i>et al.</i> , Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond). 1995 Mar;88(3):331-6.	
	C182	OZINSKY <i>et al.</i> , The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Nat. Acad. Sci. 2000; 97(25):13766-71.	
	C183	PAGE <i>et al.</i> , Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000. 1997 Jun;14:216-48.	
	C184	PARK <i>et al.</i> , Immunotherapy Cancer Treatment. Reprinted from Supportive Cancer Care, Rosenbaum <i>et al.</i> 2001. Available at <a href="http://www.cancersupportivecare.com/immunotherapy.html">http://www.cancersupportivecare.com/immunotherapy.html</a> . Last accessed July 13, 2010. 3 pages.	
	C185	PARK <i>et al.</i> , Sodium Dithionite Reduction of Nitroarenes Using Viologen as an Electron Phase-Transfer Catalyst. Tetrahedron Lett. 1993;34(46):7445-46.	
	C186	PATEL <i>et al.</i> , The necrotic venom of the brown recluse spider induces dysregulated endothelial cell-dependent neutrophil activation. Differential induction of GM-CSF, IL-8, and E-selectin expression. J Clin Invest. 1994 Aug;94(2):631-42.	
	C187	PATRICK <i>et al.</i> , Paragraph 10.3: Drug optimization: strategies in drug design. In: An Introduction to Medicinal Chemistry. Oxford: Oxford University Press. January 2005. 200-218.	
	C188	PAVLETIC <i>et al.</i> , Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr;25(7):717-22.	
	C189	PAWLAS <i>et al.</i> , Novel anionic annelation tactics for construction of fused heteroaromatic frameworks. 1. Synthesis of 4-substituted pyrazolo[3,4-c]quinolines, 9-substituted pyrazolo[3,4-c]quinolines, and 1,4-dihydrochromeno[4,3-c]pyrazoles. Org Chem. 2001 Jun 15;66(12):4214-9.	
	C190	PAYVANDI <i>et al.</i> , Exogenous and Endogenous IL-10 Regulate IFN- $\alpha$ Production by Peripheral Blood Mononuclear Cells in Response to Viral Stimulation. J Immunol. 1998;160:5861-68.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	48	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C191	PESCHKE <i>et al.</i> , Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals. Eur J Med Chem. 1999;34:363-380.		
	C192	PETERSON <i>et al.</i> , The opioid-cytokine connection. J Neuroimmunol. 1998;83:63-69.		
	C193	PHILLIPS <i>et al.</i> , Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med. 1995 Mar;25(3):363-8.		
	C194	PICKERSGILL <i>et al.</i> , Preparation of functionalized, conformationally constrained DTPA analogues from L- or D-serine and trans-4-hydroxy-L-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone. J Org Chem. 2000 Jun 30;65(13):4048-57.		
	C195	POLJAKOVIC <i>et al.</i> , iNOS and COX-2 immunoreactivity in the mice bladder and kidney after bacterial instillation. Immunology Lett. 1999;69(1):122. Abstract #31.5.		
	C196	POWELL <i>et al.</i> , Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998 Sep-Oct;52(5):238-311.		
	C197	PRELOG <i>et al.</i> , Cycloalkeno-pyridine. Helv Chem Acta. 1945;28:1684-93. German.		
	C198	REES <i>et al.</i> , Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg. 1985 Nov;202(5):659-63.		
	C199	REGAN <i>et al.</i> , Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. Virology. 2009 Feb 5;384(1):135-43. Epub 2008 Dec 5.		
	C200	RHODES, Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol. 2002 Dec;130(3):363-9.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	49	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C201	RIBERA <i>et al.</i> , "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. <i>Blood Cells</i> . 1987;12(2):471-79.	
	C202	RITTER <i>et al.</i> , A new reaction of nitriles; amides from alkenes and mononitriles. <i>J Am Chem Soc</i> . 1948 Dec;70(12):4045-8.	
	C203	ROCCA <i>et al.</i> , Carbolines. Part VII. Ansindines, Convenient tools to synthesize efficient- $\beta$ -carbolines. <i>J Heterocyclic Chem</i> . 1995;32:1171-1175.	
	C204	ROCCA <i>et al.</i> , Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles. <i>Tetrahedron</i> . 1993;49(1):49-64.	
	C205	ROLLINS, Chemokines. <i>Blood</i> . 1997 Aug 1;90(3):909-28. Review.	
	C206	ROSENBERG <i>et al.</i> , Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. <i>JAMA</i> . 1994 Mar 23-30;271(12):907-13.	
	C207	ROTHEL <i>et al.</i> , The use of recombinant ovine IL-1 $\beta$ and TNF- $\alpha$ as natural adjuvants and their physiological effects in vivo. <i>Immunol Cell Biol</i> . 1998 Apr;76(2):167-72.	
	C208	ROY <i>et al.</i> , QSAR of adenosine receptor antagonists II: exploring physicochemical requirements for selective binding of 2-arylpyrazolo[3,4-c] quinoline derivatives with adenosine A1 and A3 receptor subtypes. <i>QSAR &amp; Comb Sci</i> . 2003;22:614-621.	
	C209	ROYALS <i>et al.</i> , Studies in mixed ester condensations. IV. Acylations with methyl dimethoxyacetate. <i>J Am Chem Soc</i> . 1956;78:4161-4164.	
	C210	ROZMAN <i>et al.</i> , Chronic lymphocytic leukemia. <i>N Engl J Med</i> . 1995 Oct 19;333(16):1052-7.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	50	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C211	SAKTHIVEL <i>et al.</i> Direct SnAr amination of fluorinated imidazo[4,5-c]pyridine nucleosides: efficient synthesis of 3-fluoro-3-3-deazaadenosine analogs. Tetrahedron Letters. 2005 May;46(22):3883-3887.		
	C212	SALAUN <i>et al.</i> , TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells. J of Immunology. 2006;176:4894-901.		
	C213	SALEMINK, Uber 2-Propyl-1- Und 2-Propyl-Desaza-Adenin. Recueil. 1961;80:545-55. German.		
	C214	SAMBHI <i>et al.</i> , Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4025-9.		
	C215	SAMS <i>et al.</i> , Necrotic arachnidism. J Am Acad Dermatol. 2001 Apr;44(4):561-73; quiz 573-6.		
	C216	SAUDER <i>et al.</i> , Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults. Antimicrobial Agents Chemo. 2003;47(12):3846-52.		
	C217	SCHEERLINCK, Genetic adjuvants for DNA vaccines. Vaccine. 2001 Mar 21;19(17-19):2647-56.		
	C218	SCHEUER <i>et al.</i> , Application of the Ritter reaction to mesityl oxide and chalcone. J Am Chem Soc. 1957;22:674-676.		
	C219	SCHOFIELD <i>et al.</i> , Reply. Low-Dose Interferon-alpha in Chronic Myeloid Leukemia. Ann Internal Med. 1995;122(9):728-29. 1 page.		
	C220	SCHWANDNER <i>et al.</i> , Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999 Jun 18;274(25):17406-9.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	51	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C221	SEEMAN <i>et al.</i> , Steric and Conformational Effects in Nicotine Chemistry. J Org Chem. 1981;46:3040-48.	
	C222	SERRAT <i>et al.</i> , A highly efficient and straightforward stereoselective synthesis of novel chiral $\alpha$ -acetylenic ketones. Tetrahedron: Assymetry. 1999;10:3417-30.	
	C223	SEVERA <i>et al.</i> , Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J Immunol. 2007 May 15;178(10):6208-16.	
	C224	SEYMOUR <i>et al.</i> , Cellular immunity and hypersensitivity as components of periodontal destruction. Oral Dis. 1996 Mar;2(1):96-101. Review.	
	C225	SHELBURNE <i>et al.</i> , Quantitation of Bacteroids forsythus in subgingival plaque comparison on immunoassay and quantitative polymerase chain reaction. J Microbiol Methods. 2000;39:97-107.	
	C226	SIDKY <i>et al.</i> , Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992 Jul 1;52(13):3528-33.	
	C227	SIEGAL <i>et al.</i> , The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999 Jun 11;284(5421):1835-7.	
	C228	SLETZINGER <i>et al.</i> , The Synthesis of Isomethadone. J Am Chem Soc. 1952;74:5619-20.	
	C229	SMITH <i>et al.</i> , The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, Loxosceles reclusa. Lab Invest. 1970 Jan;22(1):90-3.	
	C230	SOFINA <i>et al.</i> , C: Possibility of Predicting the Spectrum of Antitumor Effect of Drugs on the Basis of Experimental Data. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. NCI Monograph 55. NIH Publication No. 80-1933. 1980:76-8.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	52	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C231	SOMMER <i>et al.</i> , Recent Findings on How Proinflammatory Cytokines Cause Pain: Peripheral Mechanisms in Inflammatory and Neuropathic Hyperalgesia. <i>Neurosci Letts.</i> 2004;361:184-87.	
	C232	SONOGASHIRA <i>et al.</i> , A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes, and bromopyridines. <i>Tetrahedron Letts.</i> 1975;50:4467-4470.	
	C233	SORIA <i>et al.</i> , C: Possibility of Predicting the Spectrum of Antitumor Effect of Drugs on the Basis of Experimental Data. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. <i>Int J Clin Pharmacol Ther.</i> 2000 Oct;38(10):476-81.	
	C234	SPANER <i>et al.</i> , A phase I/II trial of TLR -7 agonist immunotherapy in chronic lymphocytic leukemia. <i>Leukemia.</i> 2010; 24:222-26.	
	C235	SPANER <i>et al.</i> , Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. <i>Leukemia.</i> 2006 Feb;20(2):286-95.	
	C236	SPANER <i>et al.</i> , Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. <i>Leukemia.</i> 2007 Jan;21(1):53-60. Epub 2006 Oct 26.	
	C237	SPIVEY <i>et al.</i> , Configurationally stable biaryl analogues of 4-(dimethylamino)pyridine: A novel class of chiral nucleophilic catalysts. <i>J Org Chem.</i> 1999;64:9430-9443.	
	C238	SPRUANCE <i>et al.</i> , Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. <i>J Infect Dis.</i> 2001 Jul 15;184(2):196-200. Epub 2001 Jun 8.	
	C239	STACK, Images in clinical medicine. <i>Latrodectus mactans.</i> <i>N Engl J Med.</i> 1997 Jun 5;336(23):1649.	
	C240	STANLEY, Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. <i>Clin Exp Dermatol.</i> 2002 Oct;27(7):571-7. Review.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	53	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C241	STASHENKO <i>et al.</i> , Periapical inflammatory responses and their modulation. Crit Rev Oral Biol Med. 1998;9(4):498-521.	
	C242	STEELE <i>et al.</i> , Lipxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):467-83.	
	C243	STEELE <i>et al.</i> , Potential use of lipxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs. 2000 Sep;9(9):2121-38.	
	C244	STEINMANN <i>et al.</i> , Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000 Sep;43(3):555-6.	
	C245	STILLINGS <i>et al.</i> , Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 2. Aminoalkyl derivatives. J Med Chem. 1986 Nov;29(11):2280-4.	
	C246	STRANDTMANN <i>et al.</i> , Reaction of cyclic $\beta$ -diketones with 3,4-dihydroisoquinolines and related compounds. Preparation and anticancer activity of 2-substituted 1,3-cyclohexanediones. J Med Chem. 1967 Nov;10(6):1063-5.	
	C247	STRINGFELLOW, Induction of interferon with low molecular weight compounds: fluorenone esters, ethers (tilorone), and pyrimidinones. Methods Enzymol. 1981;78(Pt A):262-84.	
	C248	STRÖHER <i>et al.</i> , Progress towards the treatment of Ebola haemorrhagic fever. Expert Opin Investig Drugs. 2006 Dec;15(12):1523-35.	
	C249	SUGISAKA <i>et al.</i> , The Physicochemical properties of imiquimod, the first imidazoquinoline immune response modifier. Pharmaceutical Research. 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3030.	
	C250	SURREY <i>et al.</i> , The Synthesis of Some 3-Nitro- and 3-Amino-4-dialkylaminoalkylaminoquinoline Derivatives. J Am Chem Soc. 1951;73:2413-16.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	54	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C251	TAKEICHI <i>et al.</i> , Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. J Dent Res. 2000 Aug;79(8):1548-55.	
	C252	TAKESHITA <i>et al.</i> , Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol. 2004 Feb;16(1):17-22.	
	C253	TAKEUCHI <i>et al.</i> , Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol. 2001 Jul;13(7):933-40.	
	C254	TEMPLE <i>et al.</i> , Potential anticancer agents: 5-(N-substituted-aminocarbonyl)- and 5-(N-substituted-aminothiocarbonyl)-5,6,7,8-tetrahydrofolic acids. J Med Chem. 1988 Mar;31(3):697-700.	
	C255	THESING <i>et al.</i> , [Darstellung und Eigenschaften des $\Delta^1$ -Pyrrolin-N-oxyds.]. Chem Ber. 1959;92:1748-55. German.	
	C256	THIRUVIKRAMAN <i>et al.</i> , Synthesis and reactions of pyrazolo-[3,4-c]quinoline derivatives. Indian Journal of Chemistry. 1987;26B:695-696.	
	C257	TOMAI <i>et al.</i> , Imiquimod: in vivo and in vitro characteristics and toxicology. In: Cutaneous Infection and Therapy. Aly <i>et al.</i> , eds. Marcel Dekkar, Inc., New York. 1997:405-15.	
	C258	TOMIC <i>et al.</i> , Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity. J Immunol. 2006;176:3830-39.	
	C259	TOMIOKA <i>et al.</i> , Asymmetric Alkylation of $\alpha$ -Alkyl $\beta$ -Keto Esters. J Am Chem Soc. 1984;106:2718-19.	
	C260	TOTTERMAN <i>et al.</i> , Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980 Nov 13;288(5787):176-8.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	55	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C261	TRACY <i>et al.</i> , Studies in the Pyridine Series. II. Synthesis of 2-Methyl-3-( $\beta$ -Hydroxyethyl)pyridine and of the Pyridine Analog of Thiamine (Vitamin B2). J Org Chem. 1941;6:54-62.		
	C262	UNO <i>et al.</i> , TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27.		
	C263	UROSEVIC <i>et al.</i> , Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res. 2004 Aug 1;10(15):4959-70.		
	C264	VAN DE KERHOF, New Immunomodulatory Drugs. In: Skin and Environment: Perception and Protection. Ring <i>et al.</i> , eds., 10th EADV Congress, October 10-14, Munich, Germany. 2001;1:343-48.		
	C265	VASILAKOS <i>et al.</i> , Adjuvant Activities of Immune Response Modifier R-848: Comparison with CoG ODN. Cell Immunol. 2000;204:64-74.		
	C266	VIEWEG <i>et al.</i> , Tumor vaccines: from gene therapy to dendritic cells-the emerging frontier. Urol Clin North Am. 2003 Aug;30(3):633-43.		
	C267	VILCEK, The cytokines: An overview. In: The Cytokine Handbook, Fourth Ed. M. Lotze and A.W. Thompson (eds.), 2003;1:3-14.		
	C268	VOLHARDT, 18-5. Amides: The Least-Reactive Carboxylic Acid Derivatives. Organic Chemistry. 1987:813.		
	C269	VOLLMER <i>et al.</i> , Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75.		
	C270	WAGNER <i>et al.</i> , Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 1997 Nov;9(11):837-45.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	56	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	C271	WAGNER <i>et al.</i> , Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod. Cellular Immunology. 1999;191:10-19.			
	C272	WANG, Structure and Chemistry of 4-Hydroxy-6-methyl-2-pyridone. J Heterocyclic Chem. 1970;7:389-92.			
	C273	WARREN <i>et al.</i> , Macrophage Growth Factor CSF-1 Stimulates Human Monocyte Production of Interferon, Tumor Necrosis Factor, and Colony Stimulating Activity. J Immunol. 1986;137(7):2281-85.			
	C274	WASSERMAN <i>et al.</i> , Loxoscelism and necrotic arachnidism. J Toxicol Clin Toxicol. 1983-1984;21(4-5):451-72.			
	C275	WEDLOCK <i>et al.</i> , Physiological effects and adjuvanticity of recombinant brushtail possum TNF-alpha. Immunol Cell Biol. 1999 Feb;77(1):28-33.			
	C276	WELLS, Additivity of Mutational Effects in Proteins. Biochemistry. 1990;29(37):8509-17.			
	C277	WERMUTH, Molecular Variations Based on Isosteric Replacements. Practice of Medicinal Chemistry. 1996:203-37.			
	C278	WEXLER <i>et al.</i> , Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641-5.			
	C279	WIBAUT <i>et al.</i> , Syntheses of 3,4-Dimethylpyridine, 2,3-Dimethylpyridine and 2-Methyl-3-Ethylpyridine. Rec Trav Chim. 1944;63:231-38.			
	C280	WIERDA <i>et al.</i> , CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 1;96(9):2917-24.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	57	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C281	WIESELER-FRANK <i>et al.</i> , Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14(4):166-74.	
	C282	WILLIAMS <i>et al.</i> , Grignard Reactions to Chiral Oxazolidine Aldehydes. Tetrahedron. 1996;52:11673-94.	
	C283	WILSON <i>et al.</i> , Spiders and spider bites. Dermatol Clin. 1990 Apr;8(2):277-86.	
	C284	WRIGHT <i>et al.</i> , Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. 1997 Jul;30(1):28-32.	
	C285	WU <i>et al.</i> , Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved. J Interferon Cytokine Res. 2001 Dec;21(12):1117-27.	
	C286	YAMAMOTO <i>et al.</i> , Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002 Nov 21;420(6913):324-9.	
	C287	YEUNG-YUE <i>et al.</i> , The management of herpes simplex virus infections. Curr Opin Infect Dis. 2002 Apr;15(2):115-22.	
	C288	YUTILOV <i>et al.</i> , Synthesis and some reactions of 4-nitroimidazo[4-5-c]pyridin-2-ones. CAPLUS English Abstract DN 91:175261. VINITI. 1978:1193-78. Abstract Only.	
	C289	ZAGON <i>et al.</i> , Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res. 2003;967:37-47.	
	C290	ZAGON <i>et al.</i> , Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003;37:79-88.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,959-Conf. #9672
				Filing Date	May 22, 2006
				First Named Inventor	Larry R. Krepski
				Art Unit	1625
				Examiner Name	R. J. Desai
Sheet	58	of	58	Attorney Docket Number	C1271.70022US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C291	ZAGON <i>et al.</i> , The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002 Feb;38(3):351-76. Review.	
	C292	ZAGON <i>et al.</i> , The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 2003 Oct;37(5):290-7.	
	C293	ZAMBON, Periodontal diseases: microbial factors. Ann Periodontol. 1996 Nov;1(1):879-925.	
	C294	ZARUBIN <i>et al.</i> , Theoretical Study of Antagonists and Inhibitors of Mammalian Adenosine Deaminase: I. Adenosine and Its Aza- and Deazaanalogues. Russ J Bioorg Chem. 2002;28(4):284-92.	
	C295	ZHANG <i>et al.</i> , Structural features of azidopyridinyl neonicotinoid probes conferring high affinity and selectivity for mammalian alpha4beta2 and Drosophila nicotinic receptors. J Med Chem. 2002 Jun 20;45(13):2832-40.	
	C296	ZHU <i>et al.</i> , Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002 Dec;72(6):1154-63.	
	C297	ZHU <i>et al.</i> , Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol. 2002 Apr;71(4):686-94.	
	C298	ZIEGLER-HEITBROCK <i>et al.</i> , Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. 1989 May 1;73(6):1426-30.	
	C299	ZYRYANOV <i>et al.</i> , Heterocyclization of 1-(2'-Carbomethoxyphenyl)-5-Methyltetrazole. Chemistry of Heterocyclic Compounds. English Edition. 1981;16(12):1286-88.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.